Welcome to our dedicated page for Pliant Therapeutics SEC filings (Ticker: PLRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pliant Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company developing integrin-based therapeutics. Recent 8-K reports cover quarterly financial results, corporate updates for the PLN-101095 oncology program, material agreements, at-the-market equity offering arrangements, and amendments to the company’s stockholder rights agreement and Series A Junior Participating Preferred Purchase Rights.
Proxy and governance filings describe board composition, director retirements, committee roles, executive compensation, equity awards, and stockholder voting matters. Other material-event reports record officer appointments or departures and changes affecting security-holder rights, connecting the company’s capital structure and governance disclosures to its clinical-stage operating model.
Pliant Therapeutics’ Chief Financial Officer Keith Lamont Cummings reported an automatic sale of company stock. On January 20, 2026, a plan sold 24,002 shares of Common Stock on his behalf at a weighted average price of $1.28 per share, as part of a nondiscretionary Rule 10b5-1 arrangement.
The shares were sold by a broker over a price range of $1.245 to $1.33 between January 20 and January 22, 2026, to cover withholding taxes related to the vesting of previously granted restricted stock units. After this transaction, Cummings beneficially owned 297,214 shares of Pliant Therapeutics Common Stock, which include 1,958 shares acquired through an employee stock purchase plan.
Pliant Therapeutics Chief Human Resource Officer Lily Cheung reported a sale of company stock under a tax-withholding plan. On January 20, 2026, a company plan sold 7,534 shares of Common Stock on her behalf at a weighted-average price of $1.28 per share, in transactions intended to comply with Rule 10b5-1. The sales were executed between $1.245 and $1.33 over several days to cover withholding taxes tied to the vesting of previously granted restricted stock units.
After these transactions, Cheung beneficially owned 44,847 shares of Pliant Therapeutics Common Stock. This total includes 1,956 shares acquired through an Employee Stock Purchase Plan program, showing she continues to hold a meaningful equity position in the company.
Pliant Therapeutics President and CEO Bernard Coulie reported a sale of 89,375 shares of common stock on January 20, 2026 at a weighted average price of $1.28 per share. The filing explains this was a nondiscretionary sale under a plan intended to satisfy Rule 10b5-1, executed by a broker between prices of $1.245 and $1.33 to cover withholding taxes tied to vesting restricted stock units.
After this transaction, Coulie directly beneficially owns 505,601 shares of common stock, which include 1,959 shares acquired through an employee stock purchase program. He is also reported as indirectly owning 409,317 shares held by The Coulie/Leyman Family Trust, where he and his spouse serve as trustees; he disclaims beneficial ownership of those shares beyond his pecuniary interest.
Pliant Therapeutics, Inc. Chief Operating Officer Minnie Kuo had 6,917 shares of common stock sold on January 20, 2026 at a price of $1.28 per share. This was a nondiscretionary sale by a plan under Rule 10b5-1, carried out by a broker as part of transactions at prices ranging from $1.245 to $1.33 between January 20 and January 22, 2026. The sales were made on behalf of a group of employees, including Kuo, to cover withholding taxes related to the vesting of previously granted restricted stock units. After this transaction, Kuo beneficially owned 37,806 shares of Pliant Therapeutics common stock directly.
Pliant Therapeutics, Inc. disclosed that investment entities affiliated with Citadel and Kenneth Griffin have reported a significant shareholding in its common stock. Mr. Griffin may be deemed to beneficially own 2,991,915 Shares of Pliant, representing 4.9% of the Shares outstanding, based on 61,449,385 Shares outstanding as of November 1, 2025 from the company’s Form 10-Q. Various Citadel entities report smaller positions, with Citadel Advisors-related entities at 3.4%, Citadel Securities LLC at 1.4%, and other Citadel Securities affiliates at 1.5%.
The filing states that all reported Shares, which may include instruments convertible into Shares, are held as of the market open on January 22, 2026. The reporting group certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of Pliant, indicating a passive investment posture under the relevant ownership rules.
Morgan Stanley filed an amended Schedule 13G/A reporting its beneficial ownership in Pliant Therapeutics, Inc. common stock. The firm reports beneficial ownership of 545,228 shares, with shared voting power over 544,224 shares and shared dispositive power over 545,228 shares. This position represents 0.9% of Pliant’s common stock as of the event date of 12/31/2025.
Morgan Stanley notes that, as of this date, it has ceased to be the beneficial owner of more than five percent of this class of securities. The filing also states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Pliant Therapeutics.
Morgan Stanley filed an amended Schedule 13G/A reporting its beneficial ownership in Pliant Therapeutics, Inc. common stock. The firm reports beneficial ownership of 545,228 shares, with shared voting power over 544,224 shares and shared dispositive power over 545,228 shares. This position represents 0.9% of Pliant’s common stock as of the event date of 12/31/2025.
Morgan Stanley notes that, as of this date, it has ceased to be the beneficial owner of more than five percent of this class of securities. The filing also states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Pliant Therapeutics.
Pliant Therapeutics, Inc. reported an executive leadership change, appointing Minnie Kuo as Chief Operating Officer effective December 10, 2025. She previously served as the company’s Chief Development Officer after joining in September 2023.
Kuo is described as an experienced biotechnology and pharmaceutical executive with more than 20 years of multinational clinical development experience across respiratory, oncology, neurodegenerative, inflammatory, and infectious diseases. Her prior roles included senior positions at Vir Biotechnology, Nektar Therapeutics, Gilead Sciences, Roche/Genentech, and several clinical research organizations.
The company states that Ms. Kuo received no additional compensation at the time of her appointment as Chief Operating Officer and that there are no disclosable family relationships or related-party transactions associated with her appointment.
Pliant Therapeutics (PLRX) filed its Q3 2025 10-Q, reporting a net loss of $26.3 million for the quarter and $125.8 million year‑to‑date. Operating expenses fell sharply as the company wound down its discontinued IPF program.
Research and development expense decreased to $17.9 million (from $47.8 million a year ago), and general and administrative fell to $10.3 million (from $14.3 million). Cash, cash equivalents and short‑term investments were $243.3 million as of September 30, 2025. Net cash used in operating activities was $110.5 million for the nine months ended September 30, 2025.
The company discontinued bexotegrast in IPF after safety‑related findings and completed a restructuring that reduced its workforce by approximately 45%. In oncology, the Phase 1 trial of PLN‑101095 completed enrollment; data, including higher dose cohorts, are expected by the end of 2025. After quarter‑end, Pliant voluntarily prepaid its Oxford loan for $32.4 million, terminating the facility. Shares outstanding were 61,449,385 as of November 1, 2025.
Pliant Therapeutics filed an 8‑K announcing it furnished a press release with financial results for the third quarter ended September 30, 2025. The press release is attached as Exhibit 99.1. The company states the information in this report, including the exhibit, is furnished under Item 2.02 and is not deemed “filed” under Section 18 of the Exchange Act. The report was signed by Keith Cummings, M.D., MBA, Chief Financial Officer.
Pliant Therapeutics reported an executive change: Chief Business Officer Hans Hull resigned effective October 20, 2025. The company stated the resignation was not due to any disagreement related to operations, policies, or practices. The report was signed by Keith Cummings, M.D., MBA, in his capacity as Chief Financial Officer.